Efficacy of Probiotics, Prebiotics, and Synbiotics on Liver Enzymes, Lipid Profiles, and Inflammation in Patients with Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2024 Aug 22

PMID 39174901

Authors

Youwen Pan

Yafang Yang

Jiale Wu

Haiteng Zhou

Chao Yang

Affiliations

Soon will be listed here.

Abstract

Background: There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve the condition of patients with nonalcoholic fatty liver disease (NAFLD). The aim of this review was to evaluate the effect of microbiota-therapy on liver injury, inflammation, and lipid levels in individuals with NAFLD.

Methods: Using Pubmed, Embase, Cochrane Library, and Web of Science databases were searched for articles on the use of prebiotic, probiotic, or synbiotic for the treatment of patients with NAFLD up to March 2024.

Results: Thirty-four studies involving 12,682 individuals were included. Meta-analysis indicated that probiotic, prebiotic, and synbiotic supplementation significantly improved liver injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, SMD = -0.35; 95% CI: -0.55, -0.15; alanine aminotransferase, SMD = -0.48; 95% CI: -0.71, -0.25; alkaline phosphatase, SMD = -0.81; 95% CI: -1.55, -0.08), lipid profiles (triglycerides, SMD = -0.22; 95% CI: -0.43, -0.02), and inflammatory factors (high-density lipoprotein, SMD = -0.47; 95% CI: -0.88, -0.06; tumour necrosis factor alpha, SMD = -0.86 95% CI: -1.56, -0.56).

Conclusion: Overall, supplementation with probiotic, prebiotic, or synbiotic had a positive effect on reducing liver enzymes, lipid profiles, and inflammatory cytokines in patients with NAFLD.

Citing Articles

Preventive role of Pastinaca sativa in mitigating metabolic dysfunction-associated steatotic liver disease via modulation of metabolic endotoxemia.

Park J, Lee H, Lee Y, Yoo G, Son H, Choi S NPJ Sci Food. 2025; 9(1):20.

PMID: 39915500 PMC: 11803109. DOI: 10.1038/s41538-024-00366-8.

From Structure to Function: How Prebiotic Diversity Shapes Gut Integrity and Immune Balance.

Pedrosa L, de Vos P, Fabi J Nutrients. 2025; 16(24.

PMID: 39770907 PMC: 11678351. DOI: 10.3390/nu16244286.

Mitigates Fructose-Induced Non-Alcoholic Fatty Liver in Rats.

Ulusan M, Erdogan M, Simsek O, Gunes V, Erbas O Medicina (Kaunas). 2024; 60(10).

PMID: 39459500 PMC: 11509347. DOI: 10.3390/medicina60101713.

Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of and in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity.

Lu J, Shataer D, Yan H, Dong X, Zhang M, Qin Y Foods. 2024; 13(18).

PMID: 39335920 PMC: 11431124. DOI: 10.3390/foods13182992.

References

Mann J, Raponi M, Nobili V . Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev Gastroenterol Hepatol. 2017; 11(4):371-382. DOI: 10.1080/17474124.2017.1291340. View

Derosa G, Guasti L, DAngelo A, Martinotti C, Valentino M, Di Matteo S . Probiotic Therapy With VSL#3 in Patients With NAFLD: A Randomized Clinical Trial. Front Nutr. 2022; 9:846873. PMC: 9172906. DOI: 10.3389/fnut.2022.846873. View

Musazadeh V, Roshanravan N, Dehghan P, Ahrabi S . Effect of Probiotics on Liver Enzymes in Patients With Non-alcoholic Fatty Liver Disease: An Umbrella of Systematic Review and Meta-Analysis. Front Nutr. 2022; 9:844242. PMC: 9169800. DOI: 10.3389/fnut.2022.844242. View

Duseja A, Acharya S, Mehta M, Chhabra S, Rana S, Das A . High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019; 6(1):e000315. PMC: 6688701. DOI: 10.1136/bmjgast-2019-000315. View

Dong Y, Xu M, Chen L, Bhochhibhoya A . Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials. Ann Nutr Metab. 2019; 74(3):224-241. DOI: 10.1159/000499028. View

Vilar-Gomez E, Chalasani N . Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2017; 68(2):305-315. DOI: 10.1016/j.jhep.2017.11.013. View

Delzenne N, Kok N . Biochemical basis of oligofructose-induced hypolipidemia in animal models. J Nutr. 1999; 129(7 Suppl):1467S-70S. DOI: 10.1093/jn/129.7.1467S. View

Ebrahimi Z, Nasli-Esfahani E, Nadjarzade A, Mozaffari-Khosravi H . Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. J Diabetes Metab Disord. 2017; 16:23. PMC: 5457616. DOI: 10.1186/s40200-017-0304-8. View

Song M, Yuan F, Li X, Ma X, Yin X, Rouchka E . Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis. Biol Sex Differ. 2021; 12(1):3. PMC: 7789350. DOI: 10.1186/s13293-020-00346-z. View

10.

Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R . Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr. 2017; 64(3):413-417. DOI: 10.1097/MPG.0000000000001422. View

11.

Cho Y, Kim J . Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2015; 94(43):e1714. PMC: 4985374. DOI: 10.1097/MD.0000000000001714. View

12.

Borges Haubert N, Marchini J, Freire Carvalho Cunha S, Suen V, Padovan G, Jordao Junior A . Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers. Nutr Metab Insights. 2015; 8:1-6. PMC: 4425195. DOI: 10.4137/NMI.S24385. View

13.

Crommen S, Rheinwalt K, Plamper A, Simon M, Rosler D, Fimmers R . A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery. J Nutr. 2021; 152(2):408-418. DOI: 10.1093/jn/nxab392. View

14.

Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S . The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN. 2020; 39:53-60. DOI: 10.1016/j.clnesp.2020.06.020. View

15.

Gratz S, Mykkanen H, El-Nezami H . Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol. 2010; 16(4):403-10. PMC: 2811790. DOI: 10.3748/wjg.v16.i4.403. View

16.

Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G . Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med. 2013; 4(5):531-7. PMC: 3733183. View

17.

Nabavi S, Rafraf M, Somi M, Homayouni-Rad A, Asghari-Jafarabadi M . Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014; 97(12):7386-93. DOI: 10.3168/jds.2014-8500. View

18.

Fernandez M, Marette A . Potential Health Benefits of Combining Yogurt and Fruits Based on Their Probiotic and Prebiotic Properties. Adv Nutr. 2017; 8(1):155S-164S. PMC: 5227968. DOI: 10.3945/an.115.011114. View

19.

S Lavekar A, Raje D, Manohar T, A Lavekar A . Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol. 2017; 7(2):130-137. PMC: 5670255. DOI: 10.5005/jp-journals-10018-1233. View

20.

Rodrigo T, Dulani S, Seneviratne S, De Silva A, Fernando J, de Silva H . Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: a randomized clinical trial. Clin Exp Pediatr. 2021; 65(6):304-311. PMC: 9171460. DOI: 10.3345/cep.2021.00787. View